Cerevance Media Center

Current News

September 19, 2023

Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease

Cerevance today announced that the first subject has been dosed in the Phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics of CVN293.

READ FULL

August 28, 2023

Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023

Cerevance has been named by Fierce Biotech as one of the most promising early-stage biotechnology companies in the industry in 2023, showcased on this year’s Fierce 15 list.

READ FULL

July 10, 2023

Cerevance to Present at the Alzheimers Association International Conference

Cerevance today announced plans to present a poster presentation at the upcoming Alzheimer’s Association International Conference (AAIC), taking place in Amsterdam, Netherlands, July 16 – 20, 2023.

READ FULL

June 28, 2023

Cerevance to Present at the XVI European Meeting on Glial Cells in Health and Disease

Cerevance today announced plans to present a poster presentation at the upcoming XVI European Meeting on Glial Cells in Health and Disease, taking place in Berlin, Germany, July 8 – July 11, 2023.

READ FULL

News Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

August 31, 2023

22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium

Date:
Thursday, August 31, 2023
Time:
8:30am
Location:
Cambridge, United Kingdom
Media:
Presentation
Read full

July 10, 2023

Alzheimers Association International Conference

Date:
Sunday, July 16, 2023
Time:
8:45am – 4:15pm
Location:
Amsterdam, Netherlands
Media:
Presentation
Read full

June 28, 2023

XVI European Meeting on Glial Cells in Health and Disease

Date:
Monday, July 10, 2023
Time:
1:00pm – 4:00pm
Location:
Berlin, Germany
Media:
Poster
Read full

Events Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

May 30, 2023

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, & W9 Pharmacokinetic Study of Escalating Single & Multiple Doses of CVN766, an OX1R Highly Selective Antagonist, in Healthy Subjects

Vitolo et al (2023) A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN766, an OX1R Highly Selective Antagonist in Healthy Subjects. American Society of Clinical Psychopharmacology, Miami Beach, Florida, USA.

view

May 9, 2023

Uncovering Novel Cell Types and Therapeutic Targets in Alzheimer's Disease Using Cerevance’s NETSseq Platform and Analysis

Giuliano Stirparo, Xiao Xu, Marina Lizio, Justin Powell, Toni Cheung, Gonca Bayraktar, Louisa Christie, Megan Roberts, Gabriella Crane, David Cadwalladr, Jason Lawrence, Steven Sheardown, Bernadino Ossola, Nicola Brice, Keith Page, Lee A. Dawson & Mark Carlton (2023) Uncovering Novel Cell Types and Therapeutic Targets in Alzheimer's Disease using Cerevance’s NETSseq Platform and Analysis. Keystone Meeting: Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development, Whi

view

May 2, 2023

Phase 1 Study of CVN424, a Novel GPR6 Inverse Agonist

Margolin, D.H., Brice, N.L., Davidson, A.M., Matthews, K.L., Carlton, M.B.L. (2022) Phase I, First- In-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel GPR6 Inverse Agonist for Parkinson’s Disease. J. Pharmacol. Exp. Ther. 381: 33– 41

view

April 1, 2023

CVN424, a Novel GPR6 Inverse Agonist Demonstrates Efficacy in an Adjunctive Parkinson’s Disease Phase 2 Clinical Trial

Karl Kieburtz, David Margolin, Jordon Dubow, Kim Matthews, Roland Burli, Lee A. Dawson, Naidong Ye, Mark B Carlton, Nicola L Brice (2023) CVN424, a novel GPR6 inverse agonist demonstrates efficacy in an adjunctive Parkinson’s Disease phase 2 clinical trial. Int Conf Alzheimer’s & Parkinson’s Diseases & related neurological disorders, Gothenburg, Sweden

view

March 31, 2023

NETSseq Reveals Deep Molecular Insights Into Alzheimer’s and Parkinson’s Disease and Facilitates Identification of Novel Therapeutic Targets

Xiao Xu, Giuliano Stirparo, Marina Lizio, Justin Powell, Toni Cheung, David Cadwalladr, Jason Lawrence, Steven Sheardown, Bernadino Ossola, Nicola Brice, Keith Page, Lee A. Dawson, Mark Carlton (2023) NETSseq reveals deep molecular insights into Alzheimer’s disease progression and facilitates identification of novel therapeutic targets. Int Conf Alzheimer’s & Parkinson’s Diseases & related neurological disorders, Gothenburg, Sweden

view

March 1, 2023

NETSseq Provides Deep Molecular Insights into Alzheimer’s Disease Progression Enabling Selection of Novel Therapeutic Targets

Louisa Christie, Xiao Xu, Giuliano Stirparo, Marina Lizio, Justin Powell, Louise Dickson, Toni Cheung, David Cadwalladr, Jason Lawrence, Steven Sheardown, Bernardino Ossola, Nicola Brice, Keith Page, Lee A. Dawson & Mark Carlton (2023) NETSseq Provides Deep Molecular Insights Into Alzheimer’s Disease Progression Enabling Selection Of Novel Therapeutic Targets For Drug Discovery. Alzheimer’s Research UK Conference, Aberdeen, UK.

view